New Approaches for Measurable Residual Disease Assessment in Multiple Myeloma: Integrating NGS, Mass Spectrometry, and Next-Generation Flow Cytometry to Monitor Treatment Response - PubMed
7 days ago
- #MRD Assessment
- #Mass Spectrometry
- #Multiple Myeloma
- Measurable residual disease (MRD) is the strongest prognostic biomarker in multiple myeloma (MM).
- MRD provides deeper assessment of treatment response than conventional serological tests.
- MRD is used for risk stratification, prognostication, early relapse prediction, and as a clinical trial endpoint.
- Bone marrow-based next-generation flow cytometry and next-generation sequencing are current standards for MRD testing.
- Peripheral blood-based MRD tools like mass spectrometry (MALDI-TOF, 'MASS-FIX', 'EXENT', 'EasyM', 'M-Insight') are emerging for non-invasive monitoring.
- New technologies like droplet digital PCR, circulating tumor cell analysis, and cell-free DNA sequencing are under research.
- Clinical trials are exploring MRD's role in guiding treatment and optimizing assessment approaches.